<DOC>
	<DOCNO>NCT03070951</DOCNO>
	<brief_summary>The primary objective study demonstrate superior efficacy versus placebo OBE2109 alone combination add-back therapy reduction heavy menstrual bleeding associate uterine fibroid premenopausal woman .</brief_summary>
	<brief_title>Efficacy Safety OBE2109 Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids</brief_title>
	<detailed_description>The study prospective , randomize , parallel group , double-blind , placebo-controlled phase 3 study investigate efficacy safety OBE2109 alone combination add-back therapy treatment uterine fibroid . Subjects randomize one 5 treatment group 1:1:1:1:1 ratio .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<mesh_term>Menorrhagia</mesh_term>
	<criteria>Key Premenopausal woman screen . Body Mass Index ≥ 18 kg/m2 . Menstrual cycle ≥ 21 day ≤ 40 day . Presence uterine fibroid . Heavy menstrual blood loss 2 menstrual period assess screen use alkaline hematin method . Key The subject pregnant breastfeeding planning pregnancy within duration treatment period study . History uterus surgery would interfere study . The subject 's condition severe require surgery within 6 month regardless treatment provide . Undiagnosed abnormal uterine bleeding . Significant risk osteoporosis history , know osteoporosis metabolic bone disease .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Uterine Fibroid</keyword>
	<keyword>Leiomyomata</keyword>
	<keyword>Heavy Menstrual Bleeding</keyword>
	<keyword>HMB</keyword>
	<keyword>Heavy Uterine Bleeding</keyword>
	<keyword>Menorrhagia</keyword>
	<keyword>OBE2109 + Add-back</keyword>
</DOC>